Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Journal of Cardiovascular Pharmacology
|
May 1, 1985
Positive inotropic and electrophysiological effects of APP 201-533 can be explained by an increase of cardiac cyclic AMP
G Scholtysik, P Honerjäger, R Markstein, et al.
Journal of Cardiovascular Pharmacology
|
October 1, 1988
Pharmacological actions of DPN 205-734, a novel cardiotonic agent
R Salzmann, G Scholtysik, R Markstein, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
January 1, 1984
Forskolin and the release of noradrenaline in cerebrocortical slices
R Markstein, K Digges, N R Marshall, et al.
European Journal of Ophthalmology
|
June 9, 2006
Effects of antiglaucoma drugs GLC756, a novel dopamine D2 agonist and D1 antagonist, and timolol on endotoxin-induced TNF-alpha release in serum of rats
U W Laengle, R Markstein, V Schneider, et al.
Journal of Medicinal Chemistry
|
April 16, 1993
Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotamer-based dopamine receptor model"
M P Seiler, P Floersheim, R Markstein, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 1, 1995
New insights into the biology of schizophrenia through the mechanism of action of clozapine
N Brunello, C Masotto, L Steardo, et al.
Journal of Medicinal Chemistry
|
January 1, 1991
trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group
M P Seiler, A Hagenbach, H J Wüthrich, et al.
Journal of Neural Transmission
|
January 1, 1985
[3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors
A Closse, W Frick, R Markstein, et al.
Journal of Cardiovascular Pharmacology
|
May 1, 1985
Pharmacological actions of APP 201-533, a novel cardiotonic agent
R Salzmann, G Bormann, J W Herzig, et al.
European Journal of Ophthalmology
|
February 24, 2006
Effects of latanoprost and GLC756, a novel dopamine D2 agonist and D1 antagonist, on cultured normal human dermal fibroblasts
U W Laengle, R Markstein, D Pralet, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Journal of Cardiovascular Pharmacology
|
May 1, 1985
Positive inotropic and electrophysiological effects of APP 201-533 can be explained by an increase of cardiac cyclic AMP
G Scholtysik, P Honerjäger, R Markstein, et al.
Journal of Cardiovascular Pharmacology
|
October 1, 1988
Pharmacological actions of DPN 205-734, a novel cardiotonic agent
R Salzmann, G Scholtysik, R Markstein, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
January 1, 1984
Forskolin and the release of noradrenaline in cerebrocortical slices
R Markstein, K Digges, N R Marshall, et al.
European Journal of Ophthalmology
|
June 9, 2006
Effects of antiglaucoma drugs GLC756, a novel dopamine D2 agonist and D1 antagonist, and timolol on endotoxin-induced TNF-alpha release in serum of rats
U W Laengle, R Markstein, V Schneider, et al.
Journal of Medicinal Chemistry
|
April 16, 1993
Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotamer-based dopamine receptor model"
M P Seiler, P Floersheim, R Markstein, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 1, 1995
New insights into the biology of schizophrenia through the mechanism of action of clozapine
N Brunello, C Masotto, L Steardo, et al.
Journal of Medicinal Chemistry
|
January 1, 1991
trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group
M P Seiler, A Hagenbach, H J Wüthrich, et al.
Journal of Neural Transmission
|
January 1, 1985
[3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors
A Closse, W Frick, R Markstein, et al.
Journal of Cardiovascular Pharmacology
|
May 1, 1985
Pharmacological actions of APP 201-533, a novel cardiotonic agent
R Salzmann, G Bormann, J W Herzig, et al.
European Journal of Ophthalmology
|
February 24, 2006
Effects of latanoprost and GLC756, a novel dopamine D2 agonist and D1 antagonist, on cultured normal human dermal fibroblasts
U W Laengle, R Markstein, D Pralet, et al.
Page
of 5